哮喘患者症状相关中断的改善与短效β-激动剂使用天数减少相关。
Improvement in symptom-related disruptions is associated with fewer days of short-acting beta-agonist use in asthma.
机构信息
ResMed Science Center, San Diego, CA, USA.
ResMed Science Center, Halifax, NS, Canada.
出版信息
NPJ Prim Care Respir Med. 2022 Sep 2;32(1):31. doi: 10.1038/s41533-022-00299-3.
Abstract
Significant indirect healthcare costs are related to uncontrolled asthma, including productivity loss. Days with short-acting beta-agonist (SABA) use is associated with symptom-related disruptions at work, home, and school. Digital self-management platforms may support fewer days with SABA medication use and may reduce symptom-related disruptions.
摘要
未控制的哮喘会导致大量间接医疗成本，包括生产力损失。使用短效β激动剂（SABA）的天数与工作、家庭和学校的症状相关中断有关。数字自我管理平台可能会减少 SABA 药物使用天数，并减少与症状相关的中断。
Zotero 插件